Major Depressive Disorder Clinical Trial
Official title:
Testing the Value of Smartphone Assessments of People With Mood Disorders: A Pilot, Exploratory, Longitudinal Study
The purpose of this study is two-fold:
1. To identify the best smartphone data features (based on keyboard, sensor, voice/speech
data) that correlate with mood, anxiety, and cognitive assessments in patients with
Major Depressive Disorder (MDD) and Bipolar Depression (BD).
2. To identify the best smartphone data features (based on keyboard, sensor, voice/speech
at a) that predict relapse and remission in MDD or BD.
Progress in psychiatry will require better measurement. Currently, few clinicians use
standard rating instruments for either diagnosis or outcomes. As a result, clinicians often
fail to detect when a patient is not improving and fail to adjust treatments accordingly. Yet
even with the use of standard rating instruments, there are serious shortcomings because they
are used episodically, usually in an office environment, and they rely solely on subjective
reports. Given the importance of objective measures of mood, anxiety, and cognition, it is
critical for clinicians and patients to have better assessments if we are to achieve better
mental healthcare.
The advent of smartphones provides a potential solution for the lack of objective
measurement. The wide use of phones gives us the opportunity to collect passive, objective,
continuous data relevant to mood, anxiety, and cognition. While several studies have
demonstrated the feasibility of digital phenotyping psychiatric patients, the clinical value
of this approach has yet to be demonstrated.
Stated simply the question is: can the data from a smartphone be used in clinical practice to
improve care? Specifically, will sensor data, keyboard behavior, or voice and speech metrics
yield features that can be validated with clinical assessments? Can these features identify
relapse and remission even before clinical change is apparent with traditional ratings? Will
this information alter care and improve outcomes? This pilot investigation is designed to
answer the questions about validation and prediction by studying mood changes in patients
treated with ketamine, a rapid-acting antidepressant. The final question about care and
outcomes will be addressed separately.
Thus, the current study is a 6 month open, exploratory study that follows longitudinally
patients with MDD or BD who are receiving outpatient treatment at the Kadima Clinic. The
Kadima Clinic is a private outpatient mental health service providing a range of treatments
for people with mood disorders. All patients will be receiving ketamine treatment in the
Kadima Clinic; however, this is a study of smartphone features as digital biomarkers, not a
study of ketamine efficacy or safety. While the ketamine treatment will not be the focus of
this study, its rapid efficacy yields an ideal opportunity for testing and tuning the
Mindstrong digital phenotyping app. There will not be randomization, use of placebo, or
administration of blinded medication. Patients will be selected based on their willingness to
participate in clinical assessments and their use of a smartphone.
The design includes screening and assessment during the week prior to treatment and follow-up
at regular intervals for at least 3 weeks and no more than 6 months following treatment.
Assessments will be completed by the patient, by a trained clinical rater, and by a
significant other.
After completing the enrollment consent, the Mindstrong application (app) is installed in
each participant's smartphone. The app is resident on the participant's mobile phone for 6
months. The participant can at any time choose to uninstall the app. The Mindstrong app
unobtrusively monitors the participant's use of the mobile phone. The data captured by the
app is transmitted over secure channel to a secure data storage site on Amazon Web Services
(AWS) cloud infrastructure. All data captured by the app is encrypted.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 |